Breaking News

Lonza to Spin Out Specialty Ingredients Segment

LSI will operate independently in an effort to grow microbial control business

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lonza Group plans to spin-out its Specialty Ingredients segment (LSI), which will operate under independent management, with increased control over its operations and costs. The segment will remain fully owned by Lonza. The company already began the separation process and expects it to be complete by mid-2020. The spin-out will make around 130 roles redundant, which will impact around 50 roles in Switzerland and 35 in the U.S. Lonza is working to minimize job losses by transferring impacted e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters